We chose 4 genes (KIF25, E2F1, DIP2C, TFG) that were present in at least 4 tumor patients, were not present in the healthy population, were detected outside of patients 18, 19, 30, 34, and 38, and have the potential to serve as therapeutic targets22,23 or diagnostic and predisposing biomarkers24,25. This evidence concerns the gene DIP2C and neoplasm.